News|Articles|November 18, 2026

Severe Anemia Linked With Increase in Maternal Heart Failure Risk

Listen
0:00 / 0:00

Key Takeaways

  • Severe anemia in pregnant/postpartum women was associated with >5-fold higher odds of acute heart failure, and moderate anemia conferred a 52% odds increase versus no anemia.
  • Iron biomarkers independently tracked risk, with higher soluble transferrin receptor and lowest-quintile hepcidin linked to greater acute heart failure odds beyond hemoglobin concentration.
SHOW MORE

Iron deficiency, which pharmacists often treat with OTC supplements and adherence counseling, may be an underrecognized contributor to heart failure in pregnancy.

Pregnant and postpartum women with severe anemia had more than 5 times the odds of acute heart failure compared with women without anemia, according to a case-control study of more than 1600 women published in JAMA Cardiology.1

“Anemia affects more than one-third of pregnancies worldwide and contributes to increased maternal mortality, particularly in low- and middle-income countries,” wrote authors of the study. “Combined with the physiological demands of pregnancy, anemia can precipitate acute heart failure in women with underlying structural or functional heart disease, as indicated by the World Health Organization (WHO), yet evidence on anemia-related cardiovascular risks in pregnancy remains scarce.”

In the prospective study of 532 women with acute heart failure and 1091 controls, moderate anemia was associated with a 52% increase in acute heart failure odds.1

READ MORE: Doxycycline Use Associated with Higher Risk of Pregnancy Loss

Beyond hemoglobin levels, specific iron biomarkers demonstrated independent links with cardiac risk, as elevated soluble transferrin receptor levels and the lowest quintile of serum hepcidin were each associated with significantly higher odds of heart failure. The severity of cardiac impairment was evident because nearly 70% of cases presented in functional class III or IV, and 5.6% died within 42 days.

Crucially, adding pre-existing anemia measurements to established risk prediction models improved diagnostic discrimination for maternal heart failure, raising the area under the curve from 78% to 83%.1

These findings arrive as health organizations evaluate maternal screening protocols. United States Preventive Services Task Force data shows that iron deficiency prevalence rises across pregnancy, moving from under 7% in the first trimester to over 28% by the third.2

Although the task force concluded that evidence remains insufficient regarding routine screening in asymptomatic individuals, the American College of Obstetricians and Gynecologists (ACOG) recommends screening all pregnant women at the first prenatal visit and repeating tests between 24 and 28 weeks.2 This diagnostic gap creates a vital opportunity for primary care settings to identify vulnerable individuals before cardiac complications develop.

Pharmacy Leadership in Early Detection and Patient Counseling

Pharmacy professionals are ideally positioned to bridge screening gaps through patient assessment and point-of-care testing. Research evaluating pharmacist roles indicates that community pharmacies serve as accessible contact points where they can conduct medication reconciliations, identify early symptoms, and offer hemoglobin checks.3

In feasibility evaluations, nearly 100% of clients selected community pharmacies as their preferred location for point-of-care testing due to rapid results and convenient access. When abnormal hemoglobin levels are detected, pharmacists can initiate medication therapy management and facilitate prompt physician referrals for comprehensive cardiovascular evaluation.

Managing iron deficiency also relies on targeted counseling to optimize supplement adherence. Standard oral iron supplementation frequently causes transient gastrointestinal adverse effects such as nausea and constipation, which serve as major barriers to compliance.2,3

Pharmacists provide essential education regarding drug and food interactions that affect iron bioavailability, helping patients choose suitable formulations and adjust dietary habits to improve tolerability. Through regular follow-up, pharmacists support compliance and help patients maintain adequate iron stores throughout pregnancy.3

Advanced Iron Therapies and Collaborative Care Models

When oral supplementation is inadequate, emerging clinical trial data offer guidance on advanced therapeutic options. In the RAPIDIRON randomized trial evaluating pregnant women with moderate iron deficiency anemia, single-dose intravenous ferric carboxymaltose significantly reduced the incidence of infants with low birth weight compared with standard oral iron.4

Sensitivity analyses reveal that single-dose infusions of either ferric carboxymaltose or ferric derisomaltose achieved higher rates of maternal anemia resolution without requiring rescue blood transfusions or secondary intravenous iron. These findings suggest that updating clinical guidelines to incorporate single-dose intravenous iron could transform peripartum anemia care.

Expanding pharmacy practice to encompass comprehensive anemia care requires interprofessional collaboration and standardized toolkits.3

Collaborative practice agreements between pharmacists and physicians allow clinical specialists to adjust iron dosages, order lab tests, and oversee infusion protocols. Additionally, integrating pharmacists into national public health campaigns, such as the Anemia Mukt Bharat initiative in India, reinforces public awareness and promotes equitable access to care.1,3

By combining early pharmacy-based screening, patient-centered counseling, and evidence-based iron therapies, health systems can better safeguard maternal heart health globally.3

“Iron deficiency and iron deficiency anemia in pregnancy are public health problems associated with disparities in care. To address these disparities and help identify patients at risk, test cutoffs to diagnose iron deficiency and iron deficiency anemia, and screening recommendations based on cutoffs, need to be defined. In addition, current supplement, oral vs IV, and prevention vs treatment need to be defined,” concluded Margaret Ragni, MD, MPH, professor of medicine and clinical and translational research in the division of hematology/oncology at the University of Pittsburgh School of Medicine and director of the Hemophilia Center of Western Pennsylvania, according to Hematology Advisor.5

READ MORE: Women’s Health Resource Center

REFERENCES
1. Nair M, Choudhury S S, Sundar A, et al. Anemia and iron status in pregnant and postpartum women with acute heart failure. JAMA Cardiol. November 18, 2026. doi:10.1001/jamacardio.2026.4972
2. US Preventive Services Task Force. Screening and supplementation for iron deficiency and iron deficiency anemia during pregnancy: US Preventive Services Task Force recommendation statement. JAMA. 2024;332(11):906–913. doi:10.1001/jama.2024.15196
3. Meilianti S, John C, Duggan C, et al. How can pharmacists contribute to anaemia management? a review of literature and exploratory study on pharmacists' role in anaemia. Explor Res Clin Soc Pharm. 2023;9:100231. 2023 Feb 2. doi:10.1016/j.rcsop.2023.100231
4. Derman RJ, Bellad MB, Somannavar MS, et al. Single-dose intravenous iron vs oral iron for treatment of maternal iron deficiency anemia: a randomized clinical trial. Am J Obstet Gynecol. 2025;233(2):120.e1-120.e18. doi:10.1016/j.ajog.2025.01.037
5. Rodriguez T. Addressing iron deficiency anemia and related disparities in pregnancy. Hematology Advisor. October 25, 2024. Accessed November 17, 2026. https://www.hematologyadvisor.com/features/iron-deficiency-anemia-in-pregnancy/

Related to this article